MIRM

Mirum Pharmaceuticals Inc

94.61

Nov 11 • 3:59 PM ET +0.19 (0.20%)

94.61

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Nov 10, 7:37 AMMirum Pharmaceuticals announces that its Phase 3 AZURE-4 trial met the primary endpoint and presents new long-term brelovitug data at AASLD.

Peers: MDGL VIR TVTX PTCT RYTM RARE IVA GILD ZVRA BCRX

| Held by: VTI XBI IWM VB VBK VXF IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT
Market Cap	6.18B
Enterprise Value	6.55B
Income	-903.88M
Sales	670.78M
Book/sh	-0.83
Cash/sh	5.72
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	372
IPO	Jul 18, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	9.21
P/B	-
P/C	16.53
P/FCF	-
EV/EBITDA	-
EV/Sales	9.76
Quick Ratio	1.98
Current Ratio	2.07
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-15.22
EPS next Y	-1.25
EPS next Q	-0.62
EPS this Y	-3129.70%
EPS next Y	91.79%
EPS next 5Y	-
EPS past 3/5Y	51.26% 35.25%
Sales past 3/5Y	89.13% -
EPS Y/Y TTM	-1679.32%
Sales Y/Y TTM	42.18%
EPS Q/Q	-1319.80%
Sales Q/Q	39.63%
Earnings	Nov 03 AMC
EPS/Sales Surpr.	-78.72% 4.29%

Insider Own	17.16%
Insider Trans	-1.75%
Inst Own	95.48%
Inst Trans	3.95%
ROA	-99.78%
ROE	-760.01%
ROIC	-131.61%
Gross Margin	81.65%
Oper. Margin	-20.88%
Profit Margin	-134.75%
SMA20	8.62%
SMA50	6.24%
SMA200	-3.94%
Trades

Shs Outstand	65.21M
Shs Float	54.08M
Short Float	12.06%
Short Ratio	9.45
Short Interest	6.52M
52W High	130.00 -27.22%
52W Low	63.23 49.62%
Volatility	4.29% 4.35%
ATR (14)	4.12
RSI (14)	61.85
Beta	0.73
Rel Volume	0.77
Avg Volume	690.26K
Volume	528,517

Perf Week	-2.43%
Perf Month	18.83%
Perf Quarter	-4.21%
Perf Half Y	-13.33%
Perf YTD	19.77%
Perf Year	32.66%
Perf 3Y	230.69%
Perf 5Y	492.79%
Perf 10Y	-
Recom	1.13
Target Price	155.71
Prev Close	94.42
Price	94.61
Change %	0.20%

Consensus

Strong Buy

Avg. Price Target

$155.71

Implied Upside

+64.6%

Analysts15incl. previous ratings

Rating Distribution15 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 02, 2026	Initiated	CCitigroup	Buy	$145	+53.3%
May 19, 2026	Initiated	WWolfe Research	Outperform	$145	+53.3%
Feb 18, 2026	Initiated	RRBC Capital Mkts	Outperform	$130	+37.4%
Sep 24, 2025	Initiated	TTD Cowen	Buy	$95	+0.4%
Aug 11, 2025	Resumed	SStifel	Buy	$89	-5.9%
May 19, 2025	Resumed	HH.C. Wainwright	Buy	$73	-22.8%
Apr 17, 2024	Initiated	SStifel	Buy	$48	-49.3%
Dec 18, 2023	Reiterated	HH.C. Wainwright	Buy	$60 → $58	-38.7%
Nov 20, 2023	Resumed	JJP Morgan	Overweight	$37	-60.9%
Nov 13, 2023	Initiated	MMorgan Stanley	Overweight	$60	-36.6%
Oct 24, 2023	Initiated	CCantor Fitzgerald	Overweight	$50	-47.2%
Oct 17, 2023	Resumed	EEvercore ISI	Outperform	$62	-34.5%
Sep 20, 2023	Initiated	JJMP Securities	Mkt Outperform	$70	-26.0%
Sep 01, 2022	Initiated	CCitigroup	Buy	$38	-59.8%
Sep 20, 2021	Initiated	JJP Morgan	Overweight	$30	-68.3%
Aug 07, 2020	Upgrade	RRaymond James	Outperform → Strong Buy	$28 → $48	-49.3%
Aug 03, 2020	Initiated	HH.C. Wainwright	Buy	$52	-45.0%
Jul 31, 2020	Initiated	PPiper Sandler	Overweight	$77	-18.6%
Jun 25, 2020	Initiated	RRobert W. Baird	Outperform	$30	-68.3%
Aug 12, 2019	Initiated	RROTH Capital	Buy	$33	-65.1%

Nov-10-26 07:30AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD (Business Wire)
Nov-06-26 06:03AM	GeneDx and Mirum to provide genetic tests for cholestasis, cataracts or PBD-ZSD (Medical Device Network)
Nov-03-26 06:30PM	Mirum's Loss Widens Past Estimates As Pipeline Spending Swamps A Fourth Straight Guidance Raise (Earnings Whispers) +11.42%
03:01PM	Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Nov-02-26 07:02AM	Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting 2026 (Business Wire)
08:36PM	Loading…
Oct-27-26 08:36PM	Mirum's Booming Rare Liver Drug Sales Face A Market Fixated On Velixibat's FDA Setback (Earnings Whispers)
04:01PM	Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026 (Business Wire)
Oct-26-26 08:00AM	Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ (zilurgisertib) in Pediatric Patients Aged 6 to (Business Wire)
Oct-21-26 04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Oct-15-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-12-26 11:48AM	Mirum tees up Livmarli label expansion on Phase III liver disease study success (Clinical Trials Arena)
10:00AM	Mirum gains as Phase 3 LIVMARLI trial meets primary endpoint in liver disease (Investing.com)
08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Ultra-Rare Cholestatic Liver Diseases (Business Wire)
Oct-11-26 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Ultra-Rare Cholestatic Liver Diseases (Business Wire)
Sep-30-26 10:18AM	PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval (BioPharma Dive)
08:00AM	Loading…
Sep-28-26 08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus (Business Wire)
06:44AM	FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals (Stocktwits)
Sep-27-26 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 (Business Wire)
Sep-25-26 07:00PM	Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva (Business Wire)
02:43PM	INCY, MIRM Slip Into FDAs Weekend Decision Date On Shared Rare-Disease Pill (Stocktwits)
Sep-21-26 07:06AM	FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week (Stocktwits)
Sep-17-26 06:44PM	MIRM, INCY Stocks In Focus Will A September 26 FDA Ruling Reward This Weeks Gains? (Stocktwits) -7.07%
Sep-14-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-26 08:30AM	Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer (Business Wire)
Sep-02-26 04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-06-26 09:46AM	Citizens Says FDAs 'Unexpected' Phase 3 Request Clouds Mirums Near-Term Outlook MIRM Stock Crashes 15% (Stocktwits) -11.04%
Aug-05-26 04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Jul-29-26 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 (Business Wire)
Jul-13-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:35PM	Loading…
Jun-14-26 04:35PM	Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva (Business Wire)
Jun-11-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.89%
Jun-04-26 08:05AM	Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 (Business Wire)
May-30-26 12:00PM	Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 (Business Wire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
May-21-26 08:05AM	Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026 (Business Wire)
May-14-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.26%
May-12-26 11:56PM	Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes (Business Wire)
04:01PM	Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering (Business Wire)
08:00AM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-06-26 04:01PM	Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire) -6.50%
May-05-26 08:59AM	Idexx Claws Down A Beat As Shares Bound Higher On A Guidance Hike (Investor's Business Daily)
May-04-26 12:59PM	Why This Biotech ETF - The IBD Stock Of The Day - Just Reentered Its Buy Zone (Investor's Business Daily) +9.59%
12:05PM	The $1 Billion-Plus Opportunity That Sent Mirum Pharma Catapulting To A Record (Investor's Business Daily)
08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis (Business Wire)
May-03-26 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 (Business Wire)
Apr-29-26 04:01PM	Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 (Business Wire)
Apr-27-26 08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus (Business Wire)
Mar-16-26 08:00AM	Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Additional Rare Cholestatic Liver Diseases (Business Wire)
Mar-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-06-26 08:27AM	Mirum Completes Enrollment & Screening in Liver Disease Studies (Zacks)
Mar-05-26 08:00AM	Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus (Business Wire) -5.59%
Feb-26-26 10:50AM	Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues (Zacks) -15.13%
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Feb-25-26 08:00PM	Mirum Pharmaceuticals (MIRM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:25PM	Mirum Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update (Business Wire)
Feb-23-26 07:25PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
Feb-19-26 06:03AM	ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last? (Zacks)
Feb-18-26 04:01PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
Feb-10-26 10:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-05-26 08:51AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Business Wire) -5.51%
08:00AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (Business Wire)
Feb-03-26 02:10AM	Mirum doubles down on diversified rare disease strategy (Pharma Voice)
Jan-31-26 03:22PM	Is Mirum Pharmaceuticals on a Strong Path to Profitability? (Motley Fool)
08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
Jan-29-26 02:27PM	H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? (Insider Monkey)
Jan-27-26 06:33AM	Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline (Pharmaceutical Technology)
03:15AM	Is Mirum Pharmaceuticals About to Soar in 2026? (Motley Fool)
Jan-26-26 08:00AM	Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Jan-22-26 09:52PM	Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results (Insider Monkey)
Jan-20-26 09:38AM	CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? (Zacks)
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-13-26 05:04AM	3 Top Growth Stocks to Buy in the First Half of 2026 (Motley Fool)
Jan-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum (Business Wire)
Jan-09-26 11:55AM	Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals (Business Wire) +6.09%
Jan-07-26 04:01PM	Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.22%
Jan-06-26 08:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-04-26 04:05AM	5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right (Motley Fool)
Dec-30-25 03:07AM	Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now (Motley Fool)
Dec-23-25 01:52PM	This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone (Investor's Business Daily)
Dec-19-25 08:30AM	Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX (Business Wire) +10.61%
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 07:44AM	Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition (Insider Monkey)
Dec-09-25 09:45AM	Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald (TipRanks)
09:42AM	Mirum to buy Bluejay for up to $820m in rare liver disease push (Pharmaceutical Technology)
Dec-08-25 08:31AM	Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay (BioPharma Dive)
08:00AM	Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Dec-04-25 11:30AM	Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-03-25 06:30AM	Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 (Motley Fool)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
Dec-01-25 08:10AM	Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-25-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Nov 04 '26	Option Exercise	2.94	20,000	58,720	226,637	Nov 04 08:46 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Nov 04 '26	Sale	90.00	20,000	1,800,000	206,637	Nov 04 08:46 PM
Joanne Quan	Former Officer	Nov 04 '26	Proposed Sale	96.97	14,684	1,423,907		Nov 04 08:41 PM
CHRISTOPHER PEETZ	Officer	Nov 04 '26	Proposed Sale	90.00	20,000	1,800,000		Nov 04 04:26 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Oct 16 '26	Option Exercise	19.24	16,112	309,995	16,728	Oct 19 04:10 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Oct 06 '26	Option Exercise	17.31	12,197	211,179	206,637	Oct 06 08:38 PM
ERIC BJERKHOLT	Officer	Sep 14 '26	Proposed Sale	98.37	9,943	978,093		Sep 15 04:18 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Sep 14 '26	Sale	98.37	9,943	978,093	44,745	Sep 15 04:10 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Sep 02 '26	Sale	100.00	658	65,800	616	Sep 03 06:54 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Sep 01 '26	Option Exercise	2.94	30,000	88,080	224,440	Sep 03 06:52 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Sep 01 '26	Sale	98.68	30,000	2,960,401	194,440	Sep 03 06:52 PM
JOLANDA MARIE HOWE	Officer	Sep 02 '26	Proposed Sale	100.00	658	65,800		Sep 02 04:06 PM
CHRISTOPHER PEETZ	Officer	Sep 01 '26	Proposed Sale	98.68	30,000	2,960,319		Sep 01 04:12 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 18 '26	Option Exercise	6.27	40,000	250,800	41,274	Aug 19 06:19 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 18 '26	Sale	100.00	40,000	4,000,000	1,274	Aug 19 06:19 PM
JOLANDA MARIE HOWE	Officer	Aug 18 '26	Proposed Sale	100.00	40,000	4,000,000		Aug 18 05:24 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Aug 11 '26	Sale	99.90	6,001	599,510	36,355	Aug 12 05:14 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 10 '26	Option Exercise	2.94	20,000	58,720	214,309	Aug 11 05:41 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 10 '26	Sale	98.92	20,000	1,978,402	194,309	Aug 11 05:41 PM
ERIC BJERKHOLT	Officer	Aug 11 '26	Proposed Sale	99.90	6,001	599,510		Aug 11 04:11 PM
CHRISTOPHER PEETZ	Officer	Aug 10 '26	Proposed Sale	98.92	20,000	1,978,346		Aug 10 04:17 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 03 '26	Sale	105.29	1,840	193,734	1,274	Aug 05 04:26 PM
JOLANDA MARIE HOWE	Officer	Aug 03 '26	Proposed Sale	105.29	1,840	193,734		Aug 03 04:07 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jul 06 '26	Option Exercise	2.94	20,000	58,720	214,309	Jul 08 05:12 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jul 06 '26	Sale	122.27	20,000	2,445,382	194,309	Jul 08 05:12 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jul 06 '26	Sale	122.25	5,000	611,273	42,181	Jul 08 05:07 PM
CHRISTOPHER PEETZ	Officer	Jul 06 '26	Proposed Sale	122.27	20,000	2,445,434		Jul 06 04:10 PM
ERIC BJERKHOLT	Officer	Jul 06 '26	Proposed Sale	122.25	5,000	611,270		Jul 06 04:09 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 01 '26	Sale	120.00	2,721	326,520	3,114	Jul 02 06:01 PM
JOLANDA MARIE HOWE	Officer	Jul 01 '26	Proposed Sale	120.00	2,721	326,520		Jul 01 05:24 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jun 17 '26	Sale	101.95	2,594	264,458	5,835	Jun 18 06:39 PM
JOLANDA MARIE HOWE	Officer	Jun 17 '26	Proposed Sale	101.95	2,594	264,458		Jun 17 04:01 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jun 09 '26	Option Exercise	26.49	2,393	63,391	47,181	Jun 09 09:21 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jun 08 '26	Sale	93.82	5,000	469,077	44,788	Jun 09 09:21 PM
Radovich Peter	PRESIDENT AND COO	Jun 05 '26	Option Exercise	19.19	16,988	326,000	57,260	Jun 08 04:27 PM
ERIC BJERKHOLT	Officer	Jun 08 '26	Proposed Sale	93.81	5,000	469,073		Jun 08 04:20 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jun 01 '26	Option Exercise	2.94	30,000	88,080	224,309	Jun 02 07:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jun 01 '26	Sale	95.84	30,000	2,875,103	194,309	Jun 02 07:50 PM
Ramasastry Saira	Director	Jun 01 '26	Sale	100.00	3,977	397,700	0	Jun 02 07:50 PM
CHRISTOPHER PEETZ	Officer	Jun 01 '26	Proposed Sale	95.84	30,000	2,875,107		Jun 01 05:33 PM
SAIRA RAMASASTRY	Director	Jun 01 '26	Proposed Sale	100.00	3,977	397,700		Jun 01 04:04 PM
Ramasastry Saira	Director	May 15 '26	Option Exercise	23.51	2,000	47,020	2,000	May 18 08:32 PM
Ramasastry Saira	Director	May 15 '26	Sale	109.47	2,000	218,940	0	May 18 08:32 PM
SAIRA RAMASASTRY	Director	May 15 '26	Proposed Sale	109.47	2,000	218,940		May 15 04:07 PM
Ramasastry Saira	Director	Apr 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Apr 16 08:40 PM
Ramasastry Saira	Director	Apr 15 '26	Sale	96.90	2,000	193,800	0	Apr 16 08:40 PM
SAIRA RAMASASTRY	Director	Apr 15 '26	Proposed Sale	96.90	2,000	193,800		Apr 15 04:11 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 16 '26	Sale	91.98	7,287	670,243	49,788	Mar 17 07:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Mar 16 '26	Sale	91.98	7,287	670,243	18,864	Mar 17 07:30 PM
Ramasastry Saira	Director	Mar 16 '26	Option Exercise	23.51	2,000	47,020	2,000	Mar 17 07:30 PM
Ramasastry Saira	Director	Mar 16 '26	Sale	90.76	2,000	181,520	0	Mar 17 07:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 16 '26	Sale	91.98	16,515	1,519,015	40,272	Mar 17 07:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 16 '26	Sale	91.98	4,732	435,239	8,429	Mar 17 07:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 16 '26	Sale	91.98	40,985	3,769,714	194,309	Mar 17 07:30 PM
ERIC BJERKHOLT	Officer	Mar 16 '26	Proposed Sale	92.64	7,287	675,068		Mar 17 07:03 PM
Joanne Quan	Officer	Mar 16 '26	Proposed Sale	92.64	7,287	675,068		Mar 17 07:00 PM
Peter Radovich	Officer	Mar 16 '26	Proposed Sale	92.64	16,515	1,529,950		Mar 17 06:58 PM
Jolanda Howe	Officer	Mar 16 '26	Proposed Sale	92.64	4,732	438,372		Mar 17 06:55 PM
Christopher Peetz	Officer	Mar 16 '26	Proposed Sale	92.64	40,985	3,796,850		Mar 17 06:50 PM
SAIRA RAMASASTRY	Director	Mar 16 '26	Proposed Sale	90.76	2,000	181,520		Mar 16 04:04 PM
Radovich Peter	PRESIDENT AND COO	Mar 06 '26	Option Exercise	15.87	5,912	93,823	26,567	Mar 11 04:05 PM
Ramasastry Saira	Director	Feb 13 '26	Option Exercise	23.51	2,000	47,020	2,000	Feb 17 04:38 PM
Ramasastry Saira	Director	Feb 13 '26	Sale	102.09	2,000	204,180	0	Feb 17 04:38 PM
SAIRA RAMASASTRY	Director	Feb 13 '26	Proposed Sale	102.09	2,000	204,180		Feb 13 04:04 PM
Radovich Peter	PRESIDENT AND COO	Feb 02 '26	Sale	103.30	2,631	271,792	20,655	Feb 03 09:45 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '26	Sale	103.30	9,108	940,888	160,294	Feb 03 09:45 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '26	Sale	103.30	968	99,998	4,503	Feb 03 09:45 PM
Jolanda Howe	Officer	Feb 02 '26	Proposed Sale	103.80	968	100,478		Feb 02 08:29 PM
Peter Radovich	Officer	Feb 02 '26	Proposed Sale	103.80	2,631	273,098		Feb 02 08:25 PM
Christopher Peetz	Officer	Feb 02 '26	Proposed Sale	103.80	9,108	945,410		Feb 02 08:21 PM
Jolanda Howe	Officer	Jan 26 '26	Proposed Sale	96.92	842	81,607		Jan 28 06:47 PM
ERIC BJERKHOLT	Officer	Jan 26 '26	Proposed Sale	96.92	1,053	102,057		Jan 28 06:44 PM
Peter Radovich	Officer	Jan 26 '26	Proposed Sale	96.92	3,143	304,620		Jan 28 06:43 PM
Christopher Peetz	Officer	Jan 26 '26	Proposed Sale	96.92	6,831	662,061		Jan 28 06:40 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	96.19	1,053	101,290	43,741	Jan 27 04:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 26 '26	Sale	96.19	3,143	302,331	23,286	Jan 27 04:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 26 '26	Sale	96.19	842	80,994	3,700	Jan 27 04:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 26 '26	Sale	96.19	6,831	657,088	169,402	Jan 27 04:30 PM
Heron Patrick J	Director	Jan 23 '26	Buy	68.48	131,425	8,999,984	459,010	Jan 27 04:14 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 22 '26	Sale	93.33	926	86,419	3,042	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 22 '26	Sale	93.33	1,822	170,039	12,817	Jan 23 05:30 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 22 '26	Sale	93.33	1,421	132,615	42,127	Jan 23 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 22 '26	Sale	93.33	2,382	222,301	20,679	Jan 23 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 22 '26	Sale	93.33	7,098	662,422	163,733	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 20 '26	Sale	90.27	6,911	623,853	11,305	Jan 21 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Jan 16 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Sale	90.99	2,000	181,980	0	Jan 16 04:05 PM
SAIRA RAMASASTRY	Director	Jan 15 '26	Proposed Sale	90.99	2,000	181,980		Jan 15 04:02 PM
Ramasastry Saira	Director	Dec 22 '25	Option Exercise	23.51	5,000	117,550	5,000	Dec 23 06:52 PM
Ramasastry Saira	Director	Dec 22 '25	Sale	80.00	5,000	400,000	0	Dec 23 06:52 PM
GREY MICHAEL G	Director	Dec 19 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 23 06:50 PM
GREY MICHAEL G	Director	Dec 19 '25	Sale	78.00	50,000	3,900,000	0	Dec 23 06:50 PM
SAIRA RAMASASTRY	Director	Dec 22 '25	Proposed Sale	80.00	5,000	400,000		Dec 22 04:03 PM
Ramasastry Saira	Director	Dec 18 '25	Option Exercise	23.51	2,000	47,020	2,000	Dec 19 04:15 PM
Ramasastry Saira	Director	Dec 18 '25	Sale	69.73	2,000	139,460	0	Dec 19 04:15 PM
MICHAEL GREY	Director	Dec 19 '25	Proposed Sale	78.00	50,000	3,900,000		Dec 19 04:05 PM
SAIRA RAMASASTRY	Director	Dec 18 '25	Proposed Sale	69.73	2,000	139,460		Dec 18 04:09 PM
GREY MICHAEL G	Director	Dec 01 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 02 04:04 PM
GREY MICHAEL G	Director	Dec 01 '25	Sale	74.00	50,000	3,700,000	0	Dec 02 04:04 PM
MICHAEL GREY	Director	Dec 01 '25	Proposed Sale	74.00	50,000	3,700,000		Dec 01 04:07 PM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products pipeline includes Maralixibat, Cholbam, Ctexli, Volixibat, Brelovitug, MRM-3379, and Zilurgisertib. The company was founded by Niall O'Donnel, Michael G. Grey, and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

CEO & DirectorMr. Christopher Peetz

Ph.D.Mr. Peter Radovich M.B.A.

M.S.Mr. Eric H. Bjerkholt M.B.A.

Chief Technical OfficerDr. Jean-Luc Girardet Ph.D.

Senior Vice PresidentMr. Andrew McKibben

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

MIRM

Mirum Pharmaceuticals Inc

Upgrade your Finviz experience

All the Features.
Half the Price.